Commentary

Video

Dr Ali on the S0221 Trial of Alternative Chemo Dosing Schedules in Breast Cancer

Author(s):

Azka Ali, MD

Fact checked by:

Ashling Wahner ,Chris Ryan
Conference|San Antonio Breast Cancer Symposium

Azka Ali, MD, discusses findings from the S0221 trial of alternative adjuvant anthracycline and taxane dosing schedules in high-risk, early breast cancer.

Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute, discusses updated findings from the phase 3 S0221 trial (NCT00070564) investigating alternative adjuvant anthracycline and taxane dosing schedules in patients with high-risk, early breast cancer.

Related Videos
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Laura A. Huppert, MD
Polly Niravath, MD
Arvind N. Dasari, MD, MS
Charles E. Geyer, Jr., MD
Sattva S. Neelapu, MD
Related Content
Cancer | Image Credit: © Katsyarina – stock.adobe.com
January 9th 2025

Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

Melanoma | Maris– stock.adobe.com
January 4th 2025

BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy

Aaron T. Gerds, MD, MS, assistant professor, Department of Medicine, School of Medicine, member, Developmental Therapeutics Program, Case Comprehensive Cancer Center, physician,Department of Hematology and Medical Oncology, Cleveland Clinic; James K. McCloskey, MD, interim chief, Division of Leukemia, Hackensack John Theurer Cancer Center
October 14th 2024

Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

Kelly K. Hunt, MD, FACS, FSSO, of MD Anderson Cancer Center
January 3rd 2025

One Surgeon’s Spirit and Brilliance Lift a Whole Community

Non–Small Cell Lung Cancer | stock.adobe.com
January 2nd 2025

Pembrolizumab Plus SBRT Fails to Improve Survival in Unresected Stage I/II NSCLC